Ependymoma risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{AAM}} | {{CMG}} {{AE}} {{AAM}} | ||
==Overview== | ==Overview== | ||
Common risk factors in the development of ependymoma are | Common risk factors in the development of ependymoma are certain hereditary diseases ([[neurofibromatosis]] type II and Turcot syndrome), over-expression of [[kinetochore]] proteins, and down-regulation of [[metallothionein|metallothioneins]]. | ||
==Risk Factors== | ==Risk Factors== | ||
* Children with certain hereditary diseases, such as [[neurofibromatosis type II]] (NF2), [[Turcot syndrome]] B, and [[MEN1 syndrome]], have been found to be more frequently afflicted with ependymal tumors | * Children with certain hereditary diseases, such as [[neurofibromatosis type II]] (NF2), [[Turcot syndrome]] B, and [[MEN1 syndrome]], have been found to be more frequently afflicted with ependymal tumors. | ||
* | * Increased occurrence of ''chromosome 1q'' and proteins such as [[tenascin C]] and [[epidermal growth factor]] are associated with increased risk for developing ependymal tumors. | ||
*''ERBB2'', ''ERBB4'', and human telomerase reverse transcriptase ''TERT'' gene expression promote tumor cell proliferation, contributing to aggressive tumor behavior. | *''ERBB2'', ''ERBB4'', and human telomerase reverse transcriptase ''TERT'' gene expression promote tumor cell proliferation, contributing to aggressive tumor behavior. | ||
*High expression of epidermal growth factor receptor ''EGFR'' correlates with unfavorable outcome.<ref name="pmid16609018">{{cite journal| author=Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B et al.| title=Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. | journal=Clin Cancer Res | year= 2006 | volume= 12 | issue= 7 Pt 1 | pages= 2070-9 | pmid=16609018 | doi=10.1158/1078-0432.CCR-05-2363 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16609018 }} </ref> | *High expression of epidermal growth factor receptor ''EGFR'' correlates with unfavorable outcome.<ref name="pmid16609018">{{cite journal| author=Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B et al.| title=Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. | journal=Clin Cancer Res | year= 2006 | volume= 12 | issue= 7 Pt 1 | pages= 2070-9 | pmid=16609018 | doi=10.1158/1078-0432.CCR-05-2363 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16609018 }} </ref> | ||
*Over-expression of [[kinetochore]] proteins and down-regulation of [[metallothionein|metallothioneins]] are associated with recurrence | *Over-expression of [[kinetochore]] proteins and down-regulation of [[metallothionein|metallothioneins]] are associated with recurrence of ependymomas.<ref name="pmid20885975">{{cite journal| author=Peyre M, Commo F, Dantas-Barbosa C, Andreiuolo F, Puget S, Lacroix L et al.| title=Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis. | journal=PLoS One | year= 2010 | volume= 5 | issue= 9 | pages= e12932 | pmid=20885975 | doi=10.1371/journal.pone.0012932 | pmc=PMC2945762 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20885975 }} </ref> | ||
==References== | ==References== | ||
| Line 19: | Line 20: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
Latest revision as of 23:04, 23 September 2019
|
Ependymoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ependymoma risk factors On the Web |
|
American Roentgen Ray Society Images of Ependymoma risk factors |
|
Risk calculators and risk factors for Ependymoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]
Overview
Common risk factors in the development of ependymoma are certain hereditary diseases (neurofibromatosis type II and Turcot syndrome), over-expression of kinetochore proteins, and down-regulation of metallothioneins.
Risk Factors
- Children with certain hereditary diseases, such as neurofibromatosis type II (NF2), Turcot syndrome B, and MEN1 syndrome, have been found to be more frequently afflicted with ependymal tumors.
- Increased occurrence of chromosome 1q and proteins such as tenascin C and epidermal growth factor are associated with increased risk for developing ependymal tumors.
- ERBB2, ERBB4, and human telomerase reverse transcriptase TERT gene expression promote tumor cell proliferation, contributing to aggressive tumor behavior.
- High expression of epidermal growth factor receptor EGFR correlates with unfavorable outcome.[1]
- Over-expression of kinetochore proteins and down-regulation of metallothioneins are associated with recurrence of ependymomas.[2]
References
- ↑ Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B; et al. (2006). "Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma". Clin Cancer Res. 12 (7 Pt 1): 2070–9. doi:10.1158/1078-0432.CCR-05-2363. PMID 16609018.
- ↑ Peyre M, Commo F, Dantas-Barbosa C, Andreiuolo F, Puget S, Lacroix L; et al. (2010). "Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis". PLoS One. 5 (9): e12932. doi:10.1371/journal.pone.0012932. PMC 2945762. PMID 20885975.